Loan Defaults Disqualify 1,402

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 3
Volume 7
Issue 3

WASHINGTON--The Department of Health and Human Services has disqualified 1,402 health-care professionals from payments by the Medicare and Medicaid programs for failure to repay money borrowed under the Health Education Assistance Loans (HEAL) program. The total included 149 allopathic and 28 osteopathic physicians.

WASHINGTON--The Department of Health and Human Services has disqualified 1,402 health-care professionals from payments by the Medicare and Medicaid programs for failure to repay money borrowed under the Health Education Assistance Loans (HEAL) program. The total included 149 allopathic and 28 osteopathic physicians.

Chiropractors led the list with 737 disqualifications, followed by 246 dentists. Other disciplines included podiatrists (82) pharmacists (35), clinical psychologists (28), and optometrists (14).

Related Videos
Cretostimogene grenadenorepvec’s efficacy compares favorably with the current nonsurgical standards of care in high-risk, Bacillus Calmette Guerin–unresponsive non-muscle invasive bladder cancer.
Artificial intelligence models may be “seamlessly incorporated” into clinical workflow in the management of prostate cancer, says Eric Li, MD.
Panelists smiling at camera on a blue background.
Panelists smiling at camera on a blue background.
Robust genetic testing guidelines in the prostate cancer space must be supported by strong clinical research before they can be properly implemented, says William J. Catalona, MD.
Treatment with tisotumab vedotin may be a standard of care in second- or third-line recurrent or metastatic cervical cancer, says Brian Slomovitz, MD, MS, FACOG.
A panel of 4 experts on multiple myeloma seated at a long table
A panel of 4 experts on multiple myeloma seated at a long table
Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, experts on NRG1 fusion-positive malignancies
Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, experts on NRG1 fusion-positive malignancies
Related Content